Allogeneic CD19/BCMA CAR-T B cell autoimmune trial

ClinicalTrials.gov registered a Phase 1/2 clinical trial (NCT07507201) evaluating allogeneic CD19/BCMA CAR-T cell therapy for B cell autoimmune diseases. The dose-escalation study will assess safety, tolerability, and preliminary efficacy in autoimmune patients. Registration includes eligibility criteria, study design, and investigator contact information.

Bright Light Treatment for Cognitive Impairment in Major Depressive Disorder

ClinicalTrials.gov registered a new interventional study (NCT07508215) conducted by Peking University investigating bright light treatment for cognitive impairment in patients with Major Depressive Disorder. The study appears to be a clinical trial evaluating non-pharmacological therapeutic interventions. No regulatory action or compliance requirements are associated with this registration notice.

Venetoclax, Homoharringtonine, Azacitidine G-CSF AML Study

ClinicalTrials.gov registered a Phase 1/2 clinical study (NCT07507825) investigating the combination of Venetoclax, Homoharringtonine, Azacitidine, and G-CSF for the treatment of Acute Myeloid Leukemia (AML). The trial is registered in the ClinicalTrials.gov database maintained by the National Library of Medicine. No regulatory obligations or policy changes are associated with this registration.

Siplizumab vs Rabbit ATG kidney transplant study

The National Library of Medicine registered ClinicalTrials.gov study NCT07508787, a Phase 2/3 randomized controlled trial comparing siplizumab to rabbit anti-thymocyte globulin (ATG) for induction immunosuppression in kidney transplant recipients. The trial is sponsored to evaluate the efficacy and safety of siplizumab as an alternative to rabbit ATG in adult recipients of living or deceased donor kidneys.

Qidong Yixin Granule trial, atrial fibrillation ablation, China

The National Library of Medicine registered a new clinical trial (NCT07508618) on ClinicalTrials.gov evaluating Qidong Yixin Granule in patients undergoing atrial fibrillation ablation in China. The study is listed as sponsored by a Chinese institution. This is a routine registration entry documenting an interventional trial studying an herbal medicine intervention.

Depression rapid treatment study, UNC Chapel Hill

Depression rapid treatment study, UNC Chapel Hill

At-Risk Student Health Programs - Mental Health Services and Nurse Hiring

Virginia enacted SB33, expanding the At-Risk Program to include funding for student mental and physical health services in public schools. The bill permits funding to be used for hiring licensed practical nurses, registered nurses, and advanced practice registered nurses. The legislation takes effect July 1, 2026, and passed with unanimous support in both chambers.

Threat Assessment Training for Schools

Virginia HB1071 requires public elementary, secondary, and higher education institutions to ensure threat assessment teams receive specific training on emergency substantial risk orders and substantial risk orders within existing annual training requirements. The bill was signed into law on April 2, 2026, and takes effect July 1, 2026.

At-Risk Student Programs Funding - School Health Services

Virginia HB195 was signed into law by Governor Glenn Youngkin on April 2, 2026 (effective July 1, 2026). The bill expands permissible uses of At-Risk Program funding to include physical and mental health initiatives in public schools, specifically permitting funding for hiring licensed practical nurses, registered nurses, and advanced practice registered nurses.

Student internet safety curriculum - online scams, misinformation, AI content

Virginia Governor signed HB171 into law (Chapter 48), requiring all school divisions to expand their internet safety curriculum to include instruction on online scams, misinformation, and artificial intelligence-generated content. The bill amends existing acceptable internet use policy requirements for K-12 instruction. The legislation passed unanimously in the Senate (40-0) and with bipartisan support in the House (75-24).